



PRESS RELEASE

**Active Biotech to Present at
Jefferies 2014 Healthcare Conference**

Lund, Sweden, June 3, 2014 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at Jefferies 2014 Healthcare Conference held June 2-5, 2014 in New York, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include the **laquinimod** project, a novel oral immunomodulatory drug primarily for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical, the Phase III prostate cancer project **tasquinimod** in co-development with Ipsen, as well as **ANYARA**, Active Biotech's novel concept for tumor therapy of primarily renal cell cancer. Also, the project with **paquinimod (57-57)** and the pre-clinical **ISI** project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to – www.activebiotech.com.

The presentation will take place on **June 3**, at **4:30 p.m. EDT / 10:30 p.m. CEST**.

For further information, please contact:

Hans Kolam, CFO

Phone: +46 (0)46 19 20 44

E-mail: hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis. Also tasquinimod for the treatment of prostate cancer, with an unique mode of action, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn's and Lupus. The company has two additional projects in clinical development, ANYARA primarily for the treatment of renal cell cancer and the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 46 19 20 00

Fax: +46 46 19 11 00